Eledon Pharmaceuticals (ELDN) Net Income towards Common Stockholders (2013 - 2026)
Eledon Pharmaceuticals (ELDN) reported Net Income towards Common Stockholders of -$36.9 million for Q1 2026, down 515.58% on a YoY basis from $8.9 million in Q1 2025, and down 275.51% quarter-over-quarter from -$9.8 million in Q4 2025.
Eledon Pharmaceuticals (ELDN) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Eledon Pharmaceuticals has reported Net Income towards Common Stockholders for 14 years, with the latest figure at -$36.9 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 515.58% year-over-year to -$36.9 million; the trailing twelve-month figure through Mar 2026 stood at -$73.3 million (down 85.48% YoY), and the FY2025 full-year result was -$42.3 million, down 32.31% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$36.9 million, down from -$9.8 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $21.2 million in Q4 2024, with the low at -$58.4 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$14.4 million across 5 years, with a median of -$10.5 million in 2022.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders surged 159.35% — and 2026, when it tumbled 515.58%.
- Eledon Pharmaceuticals' Net Income towards Common Stockholders stood at -$58.4 million in 2022, then surged by 114.03% to $8.2 million in 2023, then surged by 159.35% to $21.2 million in 2024, then tumbled by 146.31% to -$9.8 million in 2025, then sank by 275.51% to -$36.9 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$36.9 million (Q1 2026), -$9.8 million (Q4 2025), and -$16.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Eledon Pharmaceuticals | 401.35 Mn | 185.32 Mn | - | -36.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.94 Mn |
| Dec 31, 2025 | -9.84 Mn |
| Sep 30, 2025 | -16.13 Mn |
| Jun 30, 2025 | -10.36 Mn |
| Mar 31, 2025 | -6.00 Mn |
| Dec 31, 2024 | 21.24 Mn |
| Sep 30, 2024 | -15.70 Mn |
| Jun 30, 2024 | -39.03 Mn |
| Mar 31, 2024 | -19.50 Mn |
| Dec 31, 2023 | 8.19 Mn |
| Sep 30, 2023 | -11.20 Mn |
| Jun 30, 2023 | -10.35 Mn |
| Mar 31, 2023 | -11.11 Mn |
| Dec 31, 2022 | -58.38 Mn |
| Sep 30, 2022 | -10.47 Mn |
| Jun 30, 2022 | -9.25 Mn |
| Mar 31, 2022 | -9.86 Mn |
| Dec 31, 2021 | 28.25 Mn |
| Sep 30, 2021 | -9.82 Mn |
| Jun 30, 2021 | -7.38 Mn |